1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial

作者：Hui‐Chuan Sun, Jun Fan, Feixia Shen, Jun Zhou, Tianqiang Song, Xue Bai, Yuqiao Zeng, Mingkai Chen, Zhimei Huang, M. Kuang, J. Cai, Jinhang Gao, D. Li, Baocai Xing, Xiaoxing Li, Tianfu Wen, Tao Peng, Yuzhu Wang, Liu Lx, Xiao‐Dong Zhu · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.08.2099 · 被引用次数：7 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Colorectal Cancer Treatments and Studies、Cholangiocarcinoma and Gallbladder Cancer Studies